SCHEMBL5584834

SCHEMBL5584834

Clc1cccc(C2CC[N]CC2)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
GRM2 Q14416 2/20 0.41
HTR1A P08908 2/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
IDO1 P14902 1/20 0.40
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
DRD2 P14416 3/20 0.37
MAP1LC3B Q9GZQ8 1/20 0.36
TP53 P04637 1/20 0.34
RECQL P46063 1/20 0.34
P2RX7 Q99572 1/20 0.34
NOTUM Q6P988 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1273995 0.86 HTR2A (0.48) HTR2AHTR2CHTR2BGRM2HTR1A
SCHEMBL3962246 0.84 TP53 (0.48) HTR2AHTR2CHTR2BGRM2HTR1A
SCHEMBL126651 0.80 CEL (0.46) HTR2AHTR2CHTR2BGRM2HTR1A
SCHEMBL24069104 0.80 CEL (0.46) HTR2AHTR2CHTR2BGRM2HTR1A
SCHEMBL245508 0.77 SLC6A2 (0.57) HTR2CHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL3397657 0.76 IDO1 (0.45) HTR2AHTR2CHTR2BGRM2HTR1A
SCHEMBL3773284 0.74 DRD2 (0.50) HTR2AHTR2CHTR2BGRM2HTR1A
SCHEMBL3794742 0.74 OPRL1 (0.41) HTR2AHTR2CHTR2BHTR1ASLC6A2
SCHEMBL8317554 0.72 MEN1 (0.43) HTR2AHTR2CHTR2BMEN1GAA
SCHEMBL4670700 0.72 GPR84 (0.45) HTR2AHTR2CHTR2BHTR1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A HTR2A 11/4885HTR2C 9/4885HTR2B 16/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A HTR2A 11/4885HTR2C 9/4885HTR2B 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.